Positron emission tomography scanning in lung cancer.
Continuing advances in imaging technology have resulted in an improved ability to evaluate thoracic malignancies with PET. Published reports demonstrate that PET provides accurate, noninvasive detection of malignancy that is useful in the characterization of nonspecific radiographic lung lesions, staging of known lung cancer, and identification of recurrent disease. Preliminary studies suggest that PET may also be able to accurately assess therapeutic response. The incorporation of PET into routine clinical practice has advanced rapidly and undoubtedly PET will continue to be an increasingly important part of the clinical assessment of patients with lung malignancy.
Lowe
Val J
VJ
Mayo Medical School PET Imaging, Department of Radiology, Mayo Clinic, Charlton 1N-215, Rochester, MI 55905, USA. vlowe@mayo.edu
D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis*; D009367:Neoplasm Staging / Q000706:statistics & numerical data; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed; D014481:United States / Q000453:epidemiology
D019788:Fluorodeoxyglucose F18